| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE37516 | CEPHALON | Acetamide derivative having defined particle size |
Oct, 2014
(9 years ago) | |
|
USRE37516 (Pediatric) | CEPHALON | Acetamide derivative having defined particle size |
Apr, 2015
(9 years ago) | |
| US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(4 months ago) | |
|
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(a month from now) | |
Provigil is owned by Cephalon.
Provigil contains Modafinil.
Provigil has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Provigil are:
- USRE37516
- USRE37516*PED
- US7297346
Provigil was authorised for market use on 24 December, 1998.
Provigil is available in tablet;oral dosage forms.
Provigil can be used as improved wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.
The generics of Provigil are possible to be released after 29 May, 2024.
Drugs and Companies using MODAFINIL ingredient
Market Authorisation Date: 24 December, 1998
Treatment: Improved wakefulness in patients with excessive daytime sleepiness associated with narcolepsy
Dosage: TABLET;ORAL
PROVIGIL family patents
